has been cited by the following article(s):
|
[1]
|
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
Diabetes Therapy,
2023
DOI:10.1007/s13300-022-01356-3
|
|
|
|
|
[2]
|
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
Diabetes Therapy,
2023
DOI:10.1007/s13300-022-01356-3
|
|
|
|
|
[3]
|
Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis
Diabetes Therapy,
2022
DOI:10.1007/s13300-021-01179-8
|
|
|
|
|
[4]
|
Evaluation of Patient Reported Satisfaction and Clinical Efficacy of Insulin Glargine 300 U/mL Versus 100 U/mL in Patients With Type 1 Diabetes Using Flash Glucose Monitoring System
Clinical Medicine Insights: Endocrinology and Diabetes,
2022
DOI:10.1177/11795514221098415
|
|
|
|
|
[5]
|
Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis
Diabetes Therapy,
2021
DOI:10.1007/s13300-021-01031-z
|
|
|
|
|
[6]
|
Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis
Diabetes Therapy,
2021
DOI:10.1007/s13300-021-01030-0
|
|
|
|
|
[7]
|
Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis
Diabetes Therapy,
2021
DOI:10.1007/s13300-021-01030-0
|
|
|
|